Summit Therapeu ADR (SMMT) 10.02 $SMMT Summit Receives

New Post Public Reply Private Reply Replies (0) Message Board

Sep 27, 2016 at 5:29 AM

Summit Therapeu ADR (SMMT) 10.02 $SMMT

Summit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular Dystrophy
GlobeNewswire - Mon Sep 26, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, today announces it has received Fast Track designation from the US Food and Drug Administration ('FDA'

for ezutromid in the treatment of DMD. Ezutromid is a utrophin modulator and represents a potential disease modifying treatment for all patients with the fatal muscle wasting disease DMD.
SMMT: 10.02 (+1.29)

Summit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community
GlobeNewswire - Mon Sep 12, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, today launches www.utrophintrials.com as an online resource for the DMD community. This website is dedicated to providing up to date information on utrophin and Summit's utrophin modulator clinical trials.
SMMT: 10.02 (+1.29)

Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2016 and Operational Progress
GlobeNewswire - Thu Sep 08, 6:00AM CDT
-- Conference call to be held 1:00pm BST / 8:00am EDT
SMMT: 10.02 (+1.29)

Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Wed Sep 07, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 18 Annual Rodman & Renshaw Global Investment Conference, 13 September 2016 at 2:35pm EDT in New York City.
SMMT: 10.02 (+1.29)

Summit Therapeutics to Report Financial Results for the Second Quarter Ended 31 July 2016 on 8 September 2016
GlobeNewswire - Mon Sep 05, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its financial results for the second quarter and half year ended 31 July 2016 on Thursday, 8 September 2016.
SMMT: 10.02 (+1.29)

Summit Reports Positive Phase 1 New Formulation Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid
GlobeNewswire - Tue Aug 09, 6:01AM CDT
-- New formulation of ezutromid achieved over a six-fold increase in maximum plasma levels in patients
SMMT: 10.02 (+1.29)

Summit Therapeutics to Present at Canaccord Genuity Growth Conference
GlobeNewswire - Fri Aug 05, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Erik Ostrowski, Chief Financial Officer, will present at the Canaccord Genuity Growth Conference, 11 August 2016 at 1:30pm EDT in Boston.
SMMT: 10.02 (+1.29)

First Patient Enrolled in Summit's PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMD
GlobeNewswire - Fri Jun 17, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, today announces that it has enrolled the first patient in PhaseOut DMD, a Phase 2 proof of concept clinical trial of ezutromid (formerly SMT C1100) in patients with DMD. Ezutromid dosing is expected to follow a screening period of up to 28 days.
SMMT: 10.02 (+1.29)

Summit Therapeutics to Host Utrophin R&D Day 15 June 2016
GlobeNewswire - Wed Jun 08, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, will host a Utrophin R&D Day featuring presentations from three DMD key opinion leaders alongside Summit's management on 15 June 2016 in New York City.
SMMT: 10.02 (+1.29)

Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and C. difficile infection ('CDI'

, today reports its financial results for the first quarter ended 30 April 2016.
SMMT: 10.02 (+1.29)

Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016
GlobeNewswire - Tue May 31, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial results for the period ending 30 April 2016 on Thursday, 2 June 2016.
SMMT: 10.02 (+1.29)

Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM Microbe 2016
GlobeNewswire - Mon May 23, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'

, announces that the Company will present additional positive Phase 2 CoDIFy trial data on ridinilazole versus standard of care, vancomycin, highlighting ridinilazole's preservation of the microbiome in the treatment of CDI. These data will be presented as posters at the ASM Microbe 2016 meeting that will be held 16-20 June in Boston, MA, US.
SMMT: 10.02 (+1.29)

Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
GlobeNewswire - Tue May 10, 6:07AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and C. difficile infection ('CDI'

, today reports its financial results for the fourth quarter and fiscal year ended 31 January 2016.
SMMT: 10.02 (+1.29)

Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
GlobeNewswire - Fri May 06, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'

, will be announcing its financial results for the fourth quarter and fiscal year ended 31 January 2016 on Tuesday, 10 May 2015.
SMMT: 10.02 (+1.29)

Summit Announces Further US Patent Granted for CDI Antibiotic Ridinilazole
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection ('CDI'

, announces the strengthening of the intellectual property estate protecting ridinilazole following the grant of a composition of matter patent by the United States Patent and Trademark Office.
SMMT: 10.02 (+1.29)

Summit's IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the US
GlobeNewswire - Tue Apr 26, 6:02AM CDT
-- Enrolment of Patients with DMD in the US Expected to Start 3Q 2016
SMMT: 10.02 (+1.29)

Summit Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 03, 6:00AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 18 Annual BIO CEO & Investor Conference, 9 February 2016 at 11:00am EST in New York City.
SMMT: 10.02 (+1.29)

Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD
GlobeNewswire - Thu Jan 21, 6:11AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, announces that it has received approval from the UK Medicines and Healthcare products Regulatory Agency and the Research Ethics Committee to initiate PhaseOut DMD, a Phase 2 proof of concept clinical trial of SMT C1100 in patients with DMD. SMT C1100 is an orally administered, small molecule utrophin modulator that the Company believes has the potential to treat all boys and young men with DMD, regardless of their underlying dystrophin gene mutation. Utrophin is functionally and structurally similar to dystrophin, a protein which is essential for the healthy function of muscles.
SMMT: 10.02 (+1.29)

Summit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile Infection
GlobeNewswire - Tue Jan 19, 6:16AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'

, announces that the European Patent Office ('EPO'

has granted a key patent covering the novel antibiotic, ridinilazole, and that the opposition period has expired with the patent having faced no challenge. The patent covers the use of ridinilazole for the treatment of infections caused by the bacterium Clostridium difficile.
SMMT: 10.02 (+1.29)

Summit Corporate Services secures multi-year service agreement with Dhama USA
PRWeb - Tue Dec 29, 7:31AM CST
Summit Corporate Services, Inc. a global outsourcing and 3rd Party Logistics solutions provider (3PL) serving the life science, medical device and consumer industries announced today that it is expanding its presence in the ecommerce/retail market by signing a multi-year outsourcing service agreement with dhamaUSA. Under this new agreement Summit will deliver a comprehensive range of retail services including: customer service, technical and product support, inventory management, warehousing, distribution, multi-channel order processing and fulfillment, invoicing, payment processing, as well as ERP hosting and financial reporting.
SMMT: 10.02 (+1.29)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

XKL Delivers MediaLight for High-Speed Optical Transport

Unpacking the MediaLight Launch Kicking off September, XKL is tossing its hat in the ring with the MediaLight Xponder and Muxponder systems. These aren't just any run-of-the-mill gizmos—nope, they're touted as top-of-the-line optical transport solutions. The talk of the town is their ability to dish out high-density 100G and 400G transport, and for geeks in the trade,...

Bitwise Pulls Plug on Dogecoin ETF Amid Market Risks

Bitwise Ditches Dogecoin ETF: End of a Speculative Era Who knew that a digital asset inspired by an internet meme would get a platform on Wall Street? Well, Bitwise did. They rallied behind Dogecoin, launching the Bitwise Dogecoin ETF, ticker BWOW. But as of September 10, 2026, the fund's journey is coming to an end with liquidation just around the corner. What Sparked...

Step Inside Henson's Creature Shop Magic in NYC

Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...

AbbVie's Bold Leap in Menstrual Migraine Treatment

AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...

Cannabis Industry Pushes for Robust Financial Services

Industry Gears Up for Financial Action Clearly, cannabis businesses are shouting louder than a vendor at a ballgame, demanding more than just the basic chips-and-soda banking service. They’re on the hunt for serious credit facilities, payments, and the traditional financial tools that most sectors take for granted. I mean, check this out: Shield Compliance just dropped...

Atli Launches: AI-Powered eSIM Revolutionizes Travel

What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...

RTI's $14M Boost: A Game-Changer for Tech Innovators

Breaking Ground in Tech Deployment The march toward commercializing new tech can be a nightmare. Ask any innovator trying to leap from lab genius to market ready, and they'll tell you the pathway is paved with hurdles—especially in the rough-and-tumble world of energy and industrial tech. RTI International's latest $14 million move? That's a massive step in leveling the...

Veteran Marketer Joins The Wisory's Advisory Board

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Crystal Risotti: Leading IT Compliance in Healthcare

A Journey Marked by Dedication and Expertise In the demanding world of healthcare technology, where regulations can make or break a company, Crystal Risotti has carved out a space for herself as a leader. Over the last 30 years, she's developed a reputation for blending regulatory expertise with practical business strategies. Her recognition as a Pinnacle Professional of...

K-9 Hero Act Aims to Ease Costs for Retired Dogs' Care

Let's Talk About the Loyalty that Dogs Deserve Who would've thought we'd be chatting about our four-legged heroes in a federal setting? But here we are, giving well-deserved attention to those furry federal agents. They're the ones who sniff out bombs and tackle crooks, and they're not asking for a retirement plan with a yacht – just some vet care! What the K-9 Hero Act...